Biofrontera prelim FY2023 revenue $33.8-34.3M, record high, up ~19% YoY

Biofrontera Inc.

2023-FY EPS reported -$13.02 revenue$34,071,000

FY 2023 revenue $33.8M-$34.3M, record high, ~19% growth vs 2022.
Q4 2023 revenue $10.4M-$10.9M, up ~5% vs Q4 2022.
Second half 2023 sales grew 34%-37% compared to prior year.
Preliminary and unaudited; final results expected in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biofrontera Inc. reported preliminary financial results for three and twelve months ended December 31, 2023.

Period: three and twelve months ended December 31, 2023
Result: preliminary results

Exact text from the filing

On January 11, 2024 Biofrontera Inc. (the "Company") issued a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.